Skip to main content
. 2020 Mar 18;20:66. doi: 10.1186/s12890-020-1101-6

Table 2.

Disease burden and results of investigations in Severe Asthma Clinic patients

Severe Asthma Clinic children (n = 23)
Hospital Admissions in the previous year 10 (43)c
Number of Hospital admissions in the previous year 3/3(0.9/1–4)d
Number of children with Positive Skin Prick Test 19 (83)c
Number of children with serum Specific IgE positive 18 (78)c
 ● Aspergillus 4 (22) c
 ● D pteronys 15 (65) c
 ● Australia treemix 4 (22) c
 ● Cat epithelia 7 (30) c
 ● Dog dander 9 (50) c
 ● Weed mix 4 (22) c
 ● Grass mix 7 (30) c
 ● Mould mix 4 (22) c
Blood eosinophils levelsa 909/800 (66/0–2900) d
Serum Immunoglobulin E (IU/mL) a 1257/1210 (1125/165–4565)d
Age at symptoms onset in yearsa 3.7/1.5 (3.9/0.5–12) d
Age at visit date in years 11.4/12 (2.7/4–16) d
ICSb (mcg/day) 1851/2000 (642/640–4000) d
Number of children with ACT score ≤ 19 17 (74) c
ACT score 14.2/12 (5.4/8–25) d
Quality of Life Questionnaire score a 5.2/5.3 (1.1/3.1–7) d
ACQ-5a 1.8/1.8 (1/0–3.8)d
PI-ED 9(38)c

 ● Anxiety

 ● Depression

5/3 (6.6/0–20)

0.6/0 (1.3/0–3)

Number of children under treatment with Azithromycin 7 (30) c
Nasal steroids 16 (70)c
Bronchoscopy 9 (39c)
Bronchoalveolar Lavage Fluid (BALF)a 7 (30) c
 ● % Macrophage 86.4/88 (12.6/68–99.5) d
 ● % Eosinophil 2.8/1.3 (7.5/0.5–21) d
 ● % Lymphocyte 7.9/7.5 (8.8/0.5–26) d
 ● % Neutrophil 4.7/1 (8.0/0.5–19) d

aBALF analysis n = 7; serum IgE n = 23; age at symptoms onset in years n = 15; blood eosinophils levels n = 21; Quality of Life questionnaire n = 13; ACQ-5 n = 14

bICS Inhaled corticosteroid;cValues presented as n (% of total)

dValues presented as Mean/median (SD/min-max)